Kawkab Scientific Bureau Pharmaceutical Import Profile — Iraq (DGFT 2022–2026)

Name: Kawkab Scientific Bureau Pharmaceutical Import Records from India — 3 Products, $3.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kawkab Scientific Bureau — Pharmaceutical Importer Profile (2026) | 3 Products, $3.9M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Kawkab Scientific Bureau?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$27.6M	729	65.8%
Ajanta Pharma Limited	$14.3M	1,599	34.2%

Kawkab Scientific Bureau sources from 2 verified Indian suppliers across 1,033 distinct formulations. Total import value: $41.9M across 2,328 shipments.

What Formulations Does Kawkab Scientific Bureau Import?

Formulation	Value	Ships
Pulmoxyl 500 (amoxycillin capsules BP	$411.2K	9
Pulmoxyl 500 (amoxicillin capsules BP	$203.2K	5
Bactoclav 625 (amoxycillin 500MG +	$200.0K	4
Supixime-100 dry syrup(cefixime for	$200.0K	4
Supixime 100 dry syrup cefixime for oral suspension USP 100MG 60 ML qty 98010 00 fac inv	$200.0K	4
Supixime 100 dry syrup cefixime for oralsuspension USP 100MG 60 ML qty 98184 00 fac	$150.0K	3
Avas 20 (atorvastatin 20MG tablets) Pack(3x10`s) (qty-102048.000

What Products Does Kawkab Scientific Bureau Import?

Top Products by Import Value

1Valsartan$2.4M 2Cefixime$1.2M 3Vildagliptin$247.4K

Kawkab Scientific Bureau Therapeutic Categories — 3 Specializations

Kawkab Scientific Bureau imports across 3 therapeutic categories, with Cardiovascular (62.5%), Advanced Antibiotics (31.1%), Advanced Diabetes Medications (6.4%) representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Cardiovascular

1 products · 62.5% · $2.4M

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Valsartan	Cardiovascular	$2.4M	78	1.2%	14
2	Cefixime	Advanced Antibiotics	$1.2M	24	0.7%

Key Metrics

Total Import Value$3.9M

Products3

Shipments107

Categories3

CountryIraq

#1 Rankings0

Indian Suppliers2

Formulations1,033

Top Categories

Cardiovascular62.5%

Advanced Antibiotics31.1%

Last updated: March 28, 2026

Kawkab Scientific Bureau — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Kawkab Scientific Bureau is a prominent pharmaceutical importer and distributor based in Baghdad, Iraq. Established in 1992, the company has grown to become one of the top five fastest-growing local pharmaceutical distribution companies in the country, securing a significant market share. Its operations encompass the importation, storage, and distribution of pharmaceutical products, including medicines, cosmetics, and medical devices, throughout Iraq.

The company's mission is to provide high-quality healthcare products at affordable prices, thereby improving accessibility to medicine for the Iraqi population. Guided by the philosophy that the health of the people is the wealth of the nation, Kawkab Scientific Bureau is committed to delivering on this commitment every single day.

2Distribution Network

Kawkab Scientific Bureau operates an extensive distribution network covering the entire Iraqi market, including major cities such as Erbil, Baghdad, Basra, Karbala, Tikrit, Sulaymaniyah, Duhok, Mosul, and Kirkuk. The company has invested in state-of-the-art warehouses with a capacity of 25,000 pallets, ensuring efficient storage and distribution of pharmaceutical products. These facilities comply with European and US-FDA guidelines of Good Distribution Practice (GDP), reflecting the company's commitment to maintaining high-quality standards in its operations.

Supplier Relationship Intelligence — Kawkab Scientific Bureau

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Kawkab Scientific Bureau's sourcing strategy exhibits a high degree of concentration, with its top three products—Valsartan, Cefixime, and Vildagliptin—accounting for 100% of its imports from India. This singular focus on a limited product range suggests a strategic choice to specialize in specific therapeutic areas, potentially allowing for deeper market penetration and expertise. However, this concentration also introduces risks associated with dependency on a narrow product portfolio, such as vulnerability to supply chain disruptions or changes in market demand for these specific medications. The company's reliance on two primary suppliers—Micro Labs Limited and Ajanta Pharma Limited—further underscores this concentration. While such focused partnerships can lead to favorable terms and streamlined operations, they also necessitate robust contingency planning to mitigate potential risks.

2Supply Chain Resilience

The resilience of Kawkab Scientific Bureau's supply chain is closely tied to its partnerships with Micro Labs Limited and Ajanta Pharma Limited. Both suppliers are established entities in the pharmaceutical industry, known for their adherence to international quality standards. This alignment ensures that the imported products meet the regulatory requirements of the Iraqi Ministry of Health. However, the company's limited supplier base may expose it to risks related to supply chain disruptions, such as production delays or geopolitical issues affecting trade routes. To enhance resilience, Kawkab Scientific Bureau may consider diversifying its supplier base and exploring alternative sourcing options.

3Strategic Implications

Kawkab Scientific Bureau's concentrated sourcing strategy positions it as a specialized distributor in the Iraqi pharmaceutical market, potentially offering competitive advantages in terms of expertise and market focus. For Indian exporters, this presents an opportunity to establish strong partnerships by aligning with the company's specific product needs and quality standards. However, the limited supplier base also indicates a potential vulnerability to supply chain disruptions. Indian exporters seeking to become alternative suppliers should emphasize reliability, compliance with international quality standards, and the ability to meet the specific therapeutic requirements of Kawkab Scientific Bureau.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Iraq — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Iraq

1Regulatory Authority & Framework

The Iraqi pharmaceutical sector is regulated by the Iraq Drug Regulatory Authority (IDRA), which operates under the Ministry of Health. IDRA oversees various aspects of pharmaceutical regulation, including marketing authorization, pricing oversight, pharmacovigilance, inspections, import permissions, and promotion rules. The regulatory framework ensures that all pharmaceutical products, whether domestically produced or imported, meet the required safety, efficacy, and quality standards. Marketing authorizations are typically time-limited, commonly for five years, and are renewable with updated data. Generics follow an abbreviated, bioequivalence-driven route, while biologics and biosimilars require comparability packages.

2Import Licensing & GMP

Import licensing in Iraq is managed by the Ministry of Health, which requires all pharmaceutical products to be registered and approved before they can be marketed. This process involves submitting evidence of Good Manufacturing Practice (GMP) compliance, ensuring that imported products meet international quality standards. The Ministry of Health's Technical Affairs Directorate oversees the registration process, which includes verifying the safety, efficacy, and quality of pharmaceutical products. GMP certificates from recognized authorities, such as the European Medicines Agency (EMA) or the World Health Organization (WHO), are typically accepted, facilitating the importation of high-quality pharmaceutical products into Iraq.

3Quality & Labeling

Pharmaceutical products imported into Iraq must comply with the country's labeling requirements, which include displaying information in writing. Additionally, Iraq has established a National Drug System that mandates comprehensive registration and tracking of all pharmaceutical products through a centralized digital platform. This system requires each product to have an electronic label featuring essential drug information, official pricing, and a unique QR code for instant verification. This labeling system enhances transparency and ensures that consumers and healthcare professionals have immediate access to critical product data, including drug names, expiry dates, manufacturer details, active ingredients, side effects, warnings, and precautions.

4Recent Regulatory Changes

In January 2023, the Iraqi government issued a decision to reduce the import of 23 types of medicines that are produced locally and fulfill the need. This policy aims to encourage domestic production and reduce reliance on imported pharmaceuticals. The decision was based on the principle of providing citizens with the right to choose their own medicine, pharmacy, and doctor. While this policy may impact the import dynamics for certain pharmaceutical products, it underscores the importance of understanding and adapting to the evolving regulatory landscape in Iraq. (ina.iq)

TransData Nexus Research · Iraq regulatory databasesMar 2026

Kawkab Scientific Bureau — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Kawkab Scientific Bureau's focus on importing specific therapeutic categories—Cardiovascular, Advanced Antibiotics, and Advanced Diabetes Medications—aligns with the prevalent health concerns in Iraq. The high import values for Valsartan and Cefixime indicate a significant demand for cardiovascular and antibiotic treatments, respectively. The inclusion of Vildagliptin in the product portfolio suggests a strategic response to the growing prevalence of diabetes in the region. By concentrating on these therapeutic areas, Kawkab Scientific Bureau aims to address critical healthcare needs and establish a strong presence in these segments of the Iraqi pharmaceutical market.

2Sourcing Profile

Kawkab Scientific Bureau's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on specific therapeutic areas. The company's reliance on two primary suppliers—Micro Labs Limited and Ajanta Pharma Limited—indicates a preference for established manufacturers known for their adherence to international quality standards. This approach ensures that the imported products meet the regulatory requirements of the Iraqi Ministry of Health and align with the company's quality assurance policies.

3Market Positioning

By specializing in the importation and distribution of specific therapeutic categories, Kawkab Scientific Bureau positions itself as a key supplier of essential medications in Iraq. Its focus on high-demand areas such as cardiovascular, antibiotic, and diabetes treatments enables the company to serve a broad segment of the Iraqi healthcare market, including hospitals, clinics, pharmacies, and government health programs. This strategic positioning allows Kawkab Scientific Bureau to meet critical healthcare needs and maintain a competitive edge in the market.

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Kawkab Scientific Bureau identified across shipments using consignee name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Kawkab Scientific Bureau's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 107 individual customs records matching Kawkab Scientific Bureau.
5.Supplier Verification: Kawkab Scientific Bureau sources from 2 verified Indian suppliers across 1,033 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

3 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Kawkab Scientific Bureau

Kawkab Scientific Bureau — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Kawkab Scientific Bureau?

What Formulations Does Kawkab Scientific Bureau Import?

What Products Does Kawkab Scientific Bureau Import?

Top Products by Import Value

Kawkab Scientific Bureau Therapeutic Categories — 3 Specializations

Import Portfolio — Top 3 by Import Value

Key Metrics

Top Categories

Kawkab Scientific Bureau — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Kawkab Scientific Bureau

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Iraq — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Kawkab Scientific Bureau — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Kawkab Scientific Bureau

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Kawkab Scientific Bureau

What products does Kawkab Scientific Bureau import from India?

Who supplies pharmaceuticals to Kawkab Scientific Bureau from India?

What is Kawkab Scientific Bureau's total pharmaceutical import value?

What therapeutic categories does Kawkab Scientific Bureau focus on?

Get Full Kawkab Scientific Bureau Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology